MIV Therapeutics, Inc.
MIV Therapeutics Announces Jesup & Lamont Maintains Buy Recommendation and Revises MIV Target Price to Reflect Reverse Split
Published in Cardiovascular Device Liability Week, August 3rd, 2008
MIV Therapeutics, Inc. (OTCBB:MIVI) (Frankfurt:MIV), a leading developer of next-generation coatings and advanced drug-delivery systems for cardiovascular stents and other implantable medical devices, announced that senior research analyst Kenneth Siri, CFA, of Jesup & Lamont Securities, maintained his Buy rating for MIV Therapeutics and adjusted his target price to $20.00 to reflect the Company's recent 1-for-10 reverse stock split.
In a research note on July 8th, Jesup & Lamont stated that the split is designed to improve the stock's marketability to institutional investors. As a result of the 1-for-10 reverse split, Siri is adjusting his price target from $2.00 per...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Device Liability Week
More Articles from Cardiovascular Device Liability Week
- Heart Disease
New heart disease findings from G.A. Mensah and co-authors described - Life Sciences
University of California, Department of Medicine publishes research in life sciences - The Committee to Protect Dogs
State's Highest Court Unanimously Rejects Dog Track Lawsuit - Abdominal Aortic Aneurysm
Study data from Tampere University provide new insights into abdominal aortic aneurysm - Abdominal Aortic Aneurysm Immunology
Research from Uppsala University, Department of Surgical Sciences has provided new information about abdominal aortic aneurysm immunology - Acute Ischemia
Research on acute ischemia published by scientists at Mayo Clinic - More from this issue of Cardiovascular Device Liability Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
